IP Library › Granted Patent US 12,258,420
Granted Patent B2
US 12,258,420 · App. 17/343,249 · Granted Mar 25, 2025

Engineered IGA antibodies and methods of use

Inventors: Jeanette Henrica Wilhelmina Leusen (Utrecht, NL); Johannes Gerardus Maria Evers (Utrecht, NL); Geert Jan Van Tetering (Utrecht, NL)
Assignee: TigaTX, Inc.
C07K16/4283C07K16/283C07K16/2887A61K2039/505C07K2317/41C07K2317/51C07K2317/522C07K2317/524C07K2317/526C07K2317/565C07K2317/732C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,420
App. No.
17/343,249
Granted
Mar 25, 2025
Kind
B2
Abstract

Provided herein are engineered antibodies that comprise a modified IgA2 heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitutions or deletions in a constant region of an IgA2 domain that modify naturally occurring glycosylation site(s). Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.

Claims (23)

1. A pharmaceutical composition comprising an engineered immunoglobulin A subclass 2 (IgA2) antibody or a functional fragment thereof and a pharmaceutically acceptable carrier, diluent or excipient, wherein the engineered IgA2 antibody or a functional fragment thereof comprises an antibody antigen binding domain; and a constant domain, wherein the constant domain comprises an IgA2 heavy chain constant region, wherein the IgA2 heavy chain constant region comprises an IgA2 CH1 region, an IgA2 CH2 region, and an IgA2 CH3 region, wherein the IgA2 CH3 region comprises:

(a) an amino acid substitution at N135, and

(b) a deletion of C147 and Y148,

each relative to a wildtype (WT) IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

2. The pharmaceutical composition of claim 1 , wherein the IgA2 CH1 region comprises an amino acid substitution at P124, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

3. The pharmaceutical composition of claim 2 , wherein the amino acid substitution at P124 is P124R, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

4. The pharmaceutical composition of claim 1 , wherein the IgA2 CH1 region comprises an amino acid substitution at N45.2, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

5. The pharmaceutical composition of claim 4 , wherein the amino acid substitution at N45.2 is N45.2G or N45.2A, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

6. The pharmaceutical composition of claim 1 , wherein the amino acid substitution at N135 is N135Q, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

7. The pharmaceutical composition of claim 1 , wherein the IgA2 heavy chain constant region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-21.

8. The pharmaceutical composition of claim 1 , wherein the IgA2 CH2 region comprises an Asn to Gly, an Asn to Gln, or an Asn to Thr amino acid substitution corresponding to amino acid residue 23 of SEQ ID NO: 110.

9. The pharmaceutical composition of claim 1 , wherein the IgA2 CH2 region comprises at least one amino acid substitution of a residue corresponding to any one of amino acid residues 97, 98, and 99 of SEQ ID NO: 110.

10. The pharmaceutical composition of claim 1 , wherein the IgA2 CH2 region comprises at least one amino acid substitution of a residue corresponding to amino acid residue 24 or 25 of SEQ ID NO: 110.

11. A pharmaceutical composition comprising an engineered immunoglobulin A subclass 2 (IgA2) antibody or a functional fragment thereof and a pharmaceutically acceptable carrier, diluent or excipient, wherein the engineered IgA2 antibody or functional fragment thereof comprises an antibody antigen binding domain; and a constant domain, wherein the constant domain comprises an IgA2 heavy chain constant region, wherein the IgA2 heavy chain constant region comprises an IgA2 CH1 region, an IgA2 CH2 region, and an IgA2 CH3 region, wherein

(a) the IgA2 CH1 region comprises an amino acid substitution of N45.2, and

(b) the IgA2 CH3 region comprises a deletion of residues P131 to Y148,

each relative to a wildtype (WT) IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

12. The pharmaceutical composition of claim 11 , wherein the IgA2 CH1 region comprises an amino acid substitution at P124, relative to a wildtype (WT) IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

13. The pharmaceutical composition of claim 12 , wherein the amino acid substitution at P124 is P124R, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

14. The pharmaceutical composition of claim 11 , wherein the IgA2 CH2 region comprises an Asn to Gly, an Asn to Gln, or an Asn to Thr amino acid substitution corresponding to amino acid residue 23 of SEQ ID NO: 110.

15. The pharmaceutical composition of claim 11 , wherein the IgA2 CH2 region comprises at least one amino acid substitution of a residue corresponding to any one of amino acid residues 97, 98, and 99 of SEQ ID NO: 110.

16. The pharmaceutical composition of claim 11 , wherein the IgA2 CH2 region comprises at least one amino acid substitution of a residue corresponding to amino acid residue 24 or 25 of SEQ ID NO: 110.

17. The pharmaceutical composition of claim 11 , wherein the amino acid substitution of N45.2 in the IgA2 CH1 region is N45.2G or N45.2A, relative to the WT IgA heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 according to the IMGT numbering scheme.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2021
From: UMC UTRECHT HOLDING B.V.
To: TIGA TX, INC.
Reel/Frame 057798/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: LEUSEN, JEANETTE HENRICA WILHELMINA; EVERS, JOHANNES GERARDUS MARIA; VAN TETERING, GEERT JAN
To: UMC UTRECHT HOLDING B.V.
Reel/Frame 056489/0939 →
Continuity (4)
Continuation 17091897 · Nov 6, 2020
Continuation PCTNL2020050217 · Mar 27, 2020
Provisional Application 62824864 · Mar 27, 2019
Related Publication 20210380720A1 · Dec 9, 2021
References Cited (378)
US 3270960A · Phillips · 1966 [cited by applicant]
US 3773919A · Boswell · 1973 [cited by applicant]
US 4179337A · Davis · 1979 [cited by applicant]
US 4301144A · Iwashita · 1981 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4495285A · Shimizu · 1985 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4544545A · Ryan · 1985 [cited by applicant]
US 4609546A · Hiratani · 1986 [cited by applicant]
US 4640835A · Shimizu · 1987 [cited by applicant]
US 4766106A · Katre · 1988 [cited by applicant]
US 4791192A · Nakagawa · 1988 [cited by applicant]
US 4837028A · Allen · 1989 [cited by applicant]
US 4892538A · Aebischer · 1990 [cited by applicant]
US 4946778A · Ladner · 1990 [cited by applicant]
US 5019369A · Presant · 1991 [cited by applicant]
US 5057313A · Shih · 1991 [cited by applicant]
US 5223409A · Ladner · 1993 [cited by applicant]
US 5260203A · Ladner · 1993 [cited by applicant]
US 5283187A · Aebischer · 1994 [cited by applicant]
US 5443953A · Hansen · 1995 [cited by applicant]
US 5455030A · Ladner · 1995 [cited by applicant]
US 5747654A · Pastan · 1998 [cited by applicant]
US 5856456A · Whitlow · 1999 [cited by applicant]
US 6306393B1 · Goldenberg · 2001 [cited by applicant]
US 8236561B2 · Jones · 2012 [cited by applicant]
US 8313730B2 · Simon · 2012 [cited by applicant]
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 9505848B2 · Davis · 2016 [cited by applicant]
US 9522184B2 · Von Gunten · 2016 [cited by applicant]
US 9573996B2 · Ariaans · 2017 [cited by applicant]
US 9580501B2 · Ariaans · 2017 [cited by applicant]
US 9593147B2 · Yuji · 2017 [cited by applicant]
US 9828418B2 · El Menyawi · 2017 [cited by applicant]
US 9890216B2 · Georgiou · 2018 [cited by applicant]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 11059909B2 · Leusen · 2021 [cited by examiner]
US 20030022243A1 · Kondejewski · 2003 [cited by applicant]
US 20170058018A2 · Brown · 2017 [cited by applicant]
US 20190365717A1 · Raaben · 2019 [cited by applicant]
US 20210395395A1 · Leusen · 2021 [cited by examiner]
EP B1708391 · 2017 [cited by applicant]
WO 198705330 · 1987 [cited by applicant]
WO 199206204 · 1992 [cited by applicant]
WO 199325673 · 1993 [cited by applicant]
WO 199411026 · 1994 [cited by applicant]
WO 1995017413 · 1995 [cited by applicant]
WO 1995022625 · 1995 [cited by applicant]
WO 0109186 · 2001 [cited by applicant]
WO 200109186 · 2001 [cited by applicant]
WO 20020518702 · 2002 [cited by applicant]
WO 2003102018 · 2003 [cited by applicant]
WO 2005035572 · 2005 [cited by applicant]
WO 2005103081 · 2005 [cited by applicant]
WO 20080496432 · 2008 [cited by applicant]
WO 201003512 · 2010 [cited by applicant]
WO 2013087911 · 2013 [cited by applicant]
WO 20140659451 · 2014 [cited by applicant]
WO 20140872482 · 2014 [cited by applicant]
WO 20151386002 · 2015 [cited by applicant]
WO 20180441721 · 2018 [cited by applicant]
WO 2019059771A2 · 2019 [cited by applicant]
WO 2020154405 · 2020 [cited by applicant]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331-1342). [cited by examiner]
Stip et al(J Immunother Cancer Jul. 2023;11(7):e006948). [cited by examiner]
Launay, P. et al. Fcα receptor (CD89) mediates the development of immunoglobulin a (IgA) nephropathy (Berger's disease): Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J. Ex… [cited by applicant]
Lee, S. J. et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science (80-. ). 295, 1898-1901 (2002). [cited by applicant]
Lefranc, M.P. et al. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains.“ Dev Comp Immunol. 2005;29(3):185-203”. [cited by applicant]
Lehmann CHK, et al. “DC subset specific induction of T cell responses upon antigen uptake via activating or inhibitory Fcy receptors in vivo” J. Exp. Med 214:1509-1528. doi: 10.1084/jem.20160951. Epub Apr. 7, 2017 (11.2… [cited by applicant]
Leong, K. W. & Ding, J. L. The unexplored roles of human serum IgA. DNA Cell Biol. 33, 823 829 (2014). [cited by applicant]
Leusen, J.H.W. “Immunoreceptors: evolution, structure and therapeutic applications” EMBO Rep. 2012 12:1046-1048 (7.2). [cited by applicant]
Leusen, J.H.W., et al. “Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease” 1996. J. Exp. Med. 184:1243-1249. (13.9). [cited by applicant]
Leusen, J.H.W., et al., “A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox” 1994. J. Clin. Invest. 93:2120-212… [cited by applicant]
Leusen, J.H.W., et al., “Four novel mutations in the gene encoding gp91-phox of the human NADPH oxidase: consequences for oxidase assembly” 2000. Blood 95:666-673 (9.1). [cited by applicant]
Leusen, J.H.W., et al., “Interactions between the components of the human NADPH oxidase: a review about the Intrigues in the phox family” 1996. J. Lab Clin. Med. 128:461-476. [cited by applicant]
Leusen, J.H.W., et al., “Interactions between the cytosolic components p47-phox and p67-phox of the human NADPH oxidase that are not required for activation in the cell-free system” 1995. J. Biol. Chem. 270:11216-11221.… [cited by applicant]
Leusen, J.H.W., et al., “Pro→GIn substitution in the light chain of cytochrome b558 (p22-phox) of the human NADPH oxidase leads to defective translocation of the cytosolic proteins p47-phox and p67-phox” 1994. J. Exp. M… [cited by applicant]
Leusen, J.W.H., IgA as therapeutic antibody, Molecular Immunology, vol. 68, Issue 1, 2015, pp. 35-39, ISSN 0161-5890. [cited by applicant]
Li, B. et al. CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy. Oncoimmunology 7, 1-9 (2018). [cited by applicant]
Li, B. et al. Simultaneous exposure to FcyR and FcaR on monocytes and macrophages enhances antitumor activity in vivo. Oncotarget 8, 39356-39366 (2017). [cited by applicant]
Li, Cun et al. “Construction of a chimeric secretory IgA and its neutralization activity against avian influenza virus H5N1.” Journal of immunology research vol. 2014 (2014): 394127. doi:10.1155/2014/394127. [cited by applicant]
Li, F. et al. Mouse strains influence clearance and efficacy of antibody and antibody-drug conjugate via Fc-FcGR Interaction. Mol. Cancer Ther. 18, 780-787 (2019). [cited by applicant]
Lindmark, R., et al., Binding of Immunoglobulins to Protein A and Immunoglobulin Levels in Mammalian Journal of Immunol. Meth. 62: 1-13 (1983). [cited by applicant]
Logtenberg, M. E. W. et al. Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy. Nat. Med. 25, 612-619 (2019). [cited by applicant]
Lohse et al., Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid 2 cells for antibody-dependent cell-mediated cytotoxicity (ADCC), 3 and complement dependent cytotoxicity(CDC), British Jou… [cited by applicant]
Lohse, S. et al. “An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo” Cancer Res. Jan. 15, 2016;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub Dec. 3, 2015. (9.… [cited by applicant]
Lohse, S. et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J. Biol. Chem. 287, 25139-25150 (2012). [cited by applicant]
Lohse, S., et al., “Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing” J Immunol. 2011. 186(6):3770-8 doi: 10.4049/jimmunol.1003082. Epub Feb. 11, 2011. [cited by applicant]
Lombana, T. N. et al. Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice. MAbs 11, 1122-1138 (2019). [cited by applicant]
Lorin, V., et al., “Efficient generation of human IgA monoclonal antibodies” Journal of Immunological Methods, Elsevier Science Publishers V.B (2015) vol. 422, pp. 102-110. [cited by applicant]
Lowman, H.B., et al., Selecting High Affinity Binding Proteins by Monovalent Phage Display, 1991, Biochemistry 30: 10832-10837. [cited by applicant]
Maccallum, R.M., et al. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. Oct. 11, 1996;262(5):732-45. doi: 10.1006/jmbi.1996.0548. PMID: 8876650. [cited by applicant]
Macpherson, A. J. et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (80-. ). 288, 2222-2226 (2000). [cited by applicant]
Macpherson, A. J., et al. IgA Function in Relation to the Intestinal Microbiota. Annu. Rev. Immunol. 36, 359-381 (2018). [cited by applicant]
Macpherson, A. J., Geuking, M. B. & McCoy, K. D. Homeland Security: IgA immunity at the frontiers of the body. Trends Immunol. 33, 160-167 (2012). [cited by applicant]
Maliszewski, C.R., et al. “Expression Cloning of a Human Fc Receptor for IgA” (1990) J Exp. Med. 172:1665. [cited by applicant]
Matlung HL, et al. “Neutrophils kill antibody-opsonized cancer cells by trogoptosis” Cell Rep. Jun. 26, 2018;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082. (8.3). [cited by applicant]
Matlung, H., et al., “The CD47-SIRPα signaling axis as an innate immune checkpoint in caner”, Immunological Reviews, (2017) vol. 276, No. 1, pp. 145-164. [cited by applicant]
Matthay et al., Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone marrow Transplantation, and13-CIS-Retinoic Acid, 1999;New Engl. J. of Med vol. 341: pp. 1165-1173. [cited by applicant]
Mattu, T. S. et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J. Biol. Chem. 273, 2260-2272 (1998). [cited by applicant]
Mazur, Ni, et al., “Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness” J Infect Dis. Jan. 1, 2019;219(1):59-67. doi: 10.1093/infdis/jiy477. (6.3). [cited by applicant]
Mccafferty, J. et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Doman” (1990) Nature 348:552-554). [cited by applicant]
Mcintosh, R.S., et al., “The importance of human FcgammaRI in mediating protection to malaria” 2007 PLOS Pathog. 3:e72 (8.1). [cited by applicant]
Mester, S, et al., ““Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo”” MAbs. Jan. 2021-Dec.;13(1):1893888. doi: 10.1080/1942086… [cited by applicant]
Meulenbroek, L.A.P.M., et al., “IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors” J Immunol. 2013 191:3526-3533. (5.6). [cited by applicant]
Meyer et al., 2016, Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting, MAbsvol 8. pp. 87-98. [cited by applicant]
Meyer, S, et al. “New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies” Br J Haematol. Mar. 2018;180(6):808-820. doi: 10.1111/bjh.15132. Epub Feb. 22, 2018. (5.7). [cited by applicant]
Meyer, S., et al. “Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer” MAbs. Jul. 1, 2014;6(5). [Epub ahead of print] Review. (5.3). [cited by applicant]
Mora, J, Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, Expert review of clinical pharmacology, pp. 1-7; http://dx.doi.org/10.1586/17512433.2016.1160775. [cited by applicant]
Morgan, R.A. and Anderson, W.F. “Human Gene Therapy” 1993, Ann. Rev. Biochem. 62:191-217; May 1993. [cited by applicant]
Morrell, A. et al, Metabolic Properties of Human IgA Subclasses, 1973, Clin Exp Immunol 13(4): 521-528. [cited by applicant]
Muda, M. et al. Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono-and bispecific antibodies. Protein Eng. Des. Sel. 24, 447-454 (2011). [cited by applicant]
Mulligan, R.C., “The Basic Science of Gene Therapy” 1993, Science 260:926-932. [cited by applicant]
Muyldermans, S. et al., “Recognition of Antigens by Single-Domain Antibody Fragments: the Superfluous Luxury of Paired Domains” Trend Biochemical Science (2001) 26: 230-235. [cited by applicant]
Nassin et al 2018, Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy, Biol Blood Marrow Transplant 24(3): 452-459). [cited by applicant]
Navid et al 2014, Phase I Trial of a Novelanti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity inChildren With Refractory or Recurrent Neuroblastoma, J Clin Oncol 32(14): 1445-1452. [cited by applicant]
Nederend, M, et al., “Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV” Front Immunol. Aug. 6, 2020;11:1701. doi: 10.3389/fimmu.2020.01701.eCollection 2020.PMID:32849597 … [cited by applicant]
Ner, et al., Laboratory Methods A Simple & Efficient Procedure for Generating Random Point Mutations and for Codon Replacements 1988, DNA 7: 127. [cited by applicant]
Ness et al., “DNA Shuffling of Subgenomic Sequences of Subtilisin” 1999, Nature Biotechnology 17: 893-896. [cited by applicant]
Nilson B. H., et al.. Protein L from Peptostreptococcus magnus binds to the K light chain variable domain. J. Biol. Chem. 267, 2234-2239 (1992). [cited by applicant]
Olde Nordkamp, M.J.M., et al. “Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2” J Innate Immun. 2014 6:284-292. [cited by applicant]
Osbourn et al., Directed Selection of MIP-1α neutralizing CCR5 Antibodies from a Phage Display Human Antibody Library Nat. Biotechnol., 16: 778 (1998)). [cited by applicant]
Otten, M.A., et al., “FcR γ-chain dependent signaling in immature neutrophils is mediated by FcaRI, but not by FcgRI” 2007 J. Immuno !. 179:2918-24 (5.6). [cited by applicant]
Overdijk, M.B., “Crosstalk between Human IgG Isotypes and Murine Effector Cells” J Immunol. 2012 189:3430-3438. (5,6). [cited by applicant]
Overdijk,M.B., et al. “The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking” J Immunol. Jun. 17, 2016. pii: 1501351. [Epub ahead of print] (5.6). [cited by applicant]
Padlan, E A et al. “Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex.” Proceedings of the National Academy of Sciences of the United States of America vol. 86, 15 (1989): … [cited by applicant]
Parren, P.W., et al., “Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? ”2003. Trends Immunol. 24:467-469 (10.4). [cited by applicant]
Pascal, Virginie et al., (2012) Anti-CD20 IgA Can Protect Mice Against Lymphoma Development: Evaluation of the Direct Impact of IgA and Cytotoxic Effector Recruitment on CD20 Target Cells, Haematologica, pp. 1686-1694 D… [cited by applicant]
Pasquier, B. et al. Identification of FcαRI as an inhibitory receptor that controls inflammation: Dual role of FcRγ ITAM. Immunity 22, 31-42 (2005). [cited by applicant]
Pfaffenbach et al., Activation of the Guinea Pig Alternative Complement Pathway by Mouse IgA Immune Complexes, The Journal of Experimental medicine. 1982;155(1):231-47. [cited by applicant]
Pleass, et al., Identification of Residues in the CH2/CH3 Domain Interface of IgA Essential for Interaction with the Human Fca Receptor (FcaR) CD89*) The Journal of Biological Chemistry (1999) vol. 274, No. 33, pp. 2350… [cited by applicant]
Plomp, R. et al. Comparative glycomics of immunoglobulin A and G from saliva and plasma reveals biomarker potential. Front. Immunol. 9, 1-12 (2018). [cited by applicant]
Posgai, et al., “FcaRI binding at the IgA1 Ch2-Ch3 interface induces long-range conformational changes that are transmitted to the hinge region” PNAS (2018) vol. 115, No. 38. [cited by applicant]
Presta, L.G., et al., “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and other Disorders”, Cancer Res. 57:4593-4599 (1997). [cited by applicant]
Raaz, D., et al., “FcγRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease” Atherosclerosis. 2009 205:512-6 (4.0). [cited by applicant]
Raaz-Schrauder, D., et al., “Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele” Autoimmunity. 2012 45:556-564 (2.5). [cited by applicant]
Raffaghello et al., Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse, 2003 Cancer Lett, vol. 197(1-2): p. 205-209. [cited by applicant]
Rajasekaranet al., 2015, Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment, ImmunoTargets and Therapy vol. 4: 91. [cited by applicant]
Randall, et al., “Immunoglobulin isotype knowledge and application to Fc engineering” Current Opinion in Immunology, Elsevier vol. 40, pp. 62-69. [cited by applicant]
Reidhaar-Olson and Sauer, “Combinatorial Cassette Mutagenesis as a Probe of the Informational Content of Protein Sequences” 1988, Science 241: 53-57. [cited by applicant]
Reineke, U. “Antibody Epitope Mapping Using Arrays of Synthetic Peptides” 2004, Methods Mol Biol 248:443-463. [cited by applicant]
Rifai, A., et al. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J. Exp. Med. 191, 2171-2181 (2000). [cited by applicant]
Robinson, C., “Gene Therapy—Proceeding from Laboratory to Clinic” Trends in Biotechnology, vol. 11, Issue 5, 155. [cited by applicant]
Rodriguez, M.E., et al., “Fc receptor-mediated immunity against Bordetella pertussis” 2001 J. Immunol. 167:6545-6451 (5.6). [cited by applicant]
Roos et al., 2001, Human IgA Activates the Complement System Via the Mannan-Binding Lectin Pathway. J Immunol 167(5): 2861-2868. [cited by applicant]
Rösner T, et al., “Immune effector functions of human IgG2 antibodies against EGFR” Mol Cancer Ther. Jan. 2019;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341 (5,4). [cited by applicant]
Rossato, E. et al. Reversal of arthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway. Arthritis Rheumatol. 67, 1766-1777 (2015). [cited by applicant]
Roth, Z., et al., “Identification and Quantification of Protein Glycosylation” International Journal of Carbohydrate Chemistry, vol. 2012, Article ID 640923. [cited by applicant]
Rouwendal, G. J. A. et al. A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs 8, 74-86 (2016). [cited by applicant]
Roux et al. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol. Oct. 15, 1998;161(8):4083-90. PMID: 9780179. [cited by applicant]
Rudikoff, S et al. “Single amino acid substitution altering antigen-binding specificity.” Proceedings of the National Academy of Sciences of the United States of America vol. 79,6 (1982): 1979-83. doi:10.1073/pnas.79.6.… [cited by applicant]
Running Deer, J. et al., “High-Level Expression of Proteins in Mammalian Cells Using Transcription Regulatory Sequences from the Chinese Hamster EF1a Gene” Biotechnol. Prog.20:880-889 (2004). [cited by applicant]
Saeland, E., et al., “Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice” 2003. J Immunol. 170:6158-6164 (5.6). [cited by applicant]
Saeland, E., et al., “Role of leukocyte immunoglobuin G receptors in vaccine-induced immunity to [cited by applicant]
Schneider, M.P., et al. “The Fcγ receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia” Atherosclerosis. Jul. 20, 2011. (4.0). [cited by applicant]
Sharma, S. K. et al. Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res. 78, 1820-1832 (2018). [cited by applicant]
Shields, R.L., et al., Hi Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRN and Design of IgG1 Variants with Improved Bidning to the FcγR (2001) J. Biol. Chem., 276:6591-6604. [cited by applicant]
Sillevis Smitt, J.H., et al. “Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease” 1997. Arch. Dis. Child. 77:150-152. [cited by applicant]
Sitaraman, K, et al., High-Throughput Protein Expression Using Cell-Free System Methods Mol. Biol. 498: 229-44 (2009). [cited by applicant]
Smit, J.J, et al., Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses. PLoS One. 2011;6(12):e28917. doi: 10.1371/journal.pone.0028917. Epub Dec. 14, 2011. PMID: 22194949; … [cited by applicant]
Snoeck, V., et al. The IgA system: a comparison of structure and function in different species. Vet. Res. 37, 455-467 (2006). [cited by applicant]
Sorkin et al., Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia, 2010, Pain 149(1): 135-142. [cited by applicant]
Spirin, A.S. et al., “High-Throughput Cell-Free Systems for Synthesis of Funcationally Active Proteins” Trends Biotechnol. 22: 538-45 (2004). [cited by applicant]
Sprong, H., et al. Aberrant receptor-mediated endocytosis of Schistosoma mansoni glycoproteins on host lipoproteins. PLoS Med. 2006;3(8):e253. doi:10.1371/journal.pmed.0030253. [cited by applicant]
Steeghs, L., et al., “Teasing apart structural determinants of “toxicity” and “adjuvanticity”: implications for meningococcal vaccine development” 2004 J Endotoxin Res. 10:113-119. [cited by applicant]
Åhlin, M., et al., “Prevalence, clinical presentation and genetics of chronic granulomatous disease in Sweden” 1995. Acta Pediatrica 84:1386-1394. [cited by applicant]
Yu et al., “Anti-GD2 Antibody with GM-CSF, Interleukin-2,and Isotretinoin for Neuroblastoma” (2010) N Engl J Med 363(14): 1324-1334. [cited by applicant]
Zhang, W. et al. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Front. Immunol. 11, 1-15 (2020). [cited by applicant]
Zhao, X.W., et al., “CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction”, Proceedings of the National Academy of Sciences, vol. 108, No. 45, Nov. 8,… [cited by applicant]
Zhong, X. et al. Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins. Biotechnol. Prog. 35, 1-12 (2019). [cited by applicant]
Zhu, X. et al. MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells. J. Immunol. 166, 3266-3276 (2001). [cited by applicant]
Zoller, M.J., et al., “Oligonucleotide-directed Mutagenesis using M13-dervied Vectors: an Efficient and general Procedure for the Production of Point Mutations in Any Fragment of DNA” Nucl. Acids Res. 10:6487 (1982). [cited by applicant]
Klein, Christian, et al., “Epitope interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties”, MABS, col. 5, No. 1, Jan. 1, 2013, pp. 22-33. [cited by applicant]
A. Jamal, et al., “Biological Validation of Plant-Derived Anti-Human Colorectal Cancer Monoclonal Antibody CO17-1A” 2009. Hybridoma. 28:7-12. [cited by applicant]
A.B. van Spriel, et al., “Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and Immunologic synapse formation” 2001. Blood 97:2478-2486 (11.8). [cited by applicant]
Ahmed, M., et al., Engineering anti-GD2 Monoclonal Antibodies for Cancer Immunotherapy, 2014; FEBS letters588: 288-297. [cited by applicant]
Albanesi, M., et al., “FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma” J. Immunol Cutting Edge, 2012 189:5513-5517. (5.… [cited by applicant]
Allazikani et al, “Standard Conformations for the Canonical Structures of Immunoglobulins” J. Molec. Biol. (1997) 273:927-948. [cited by applicant]
Allesandri-Haber, Nicole et al., A Transient Receptor Potential Vanilloid-4-Dependent Mechanism of Hyperalgesia Is Engaged by Concerted Action of Inflammatory Mediators, The Journal of Neuroscience, Apr. 5, 2006, 26(14)… [cited by applicant]
Almagro, JC, & Fransson, J., “Humanization of antibodies” Front Biosci. Jan. 1, 2008;13:1619-33. doi: 10.2741/2786. PMID: 17981654. [cited by applicant]
Andersen, J. T. et al. “Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences i… [cited by applicant]
Armour et al. “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities.” Eur J Immunol 29(8):2613-2624 (1999). [cited by applicant]
Atkin, J. D., et al., “Mutagenesis of the human IgA1 heavy chain tailpiece that prevents dimer assembly” J. Immunol. 157, 156-9 (1996). [cited by applicant]
Baars, P.A., et al., “Cytolytic mechanisms and expression of activation-regulating receptors on effector-type, CD8+CD45RA+CD27-human T cells” 2000. J Immunol. 165:1910-1917. (5.6). [cited by applicant]
Bakema, J. E. & Van Egmond, M., “Immunoglobulin A: a next generation of therapeutic antibodies?” MAbs 3, 352-361 (2011). [cited by applicant]
Bakema, J.E., et al., “c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain” Eur. J. Immunol. 2010. 40:2035-2040 (4.5). [cited by applicant]
Bakema, J.E., et al., “Inside-out regulation of FcaRI (CD89) depends on Protein Phosphatase 2A” 2008. J. Immuno! 181:4080-4088 (5.6). [cited by applicant]
Bakema, J.E., et al., “Signaling through mutants of the IgA receptor, CD89, and consequences for FcR γ-chain Interaction” 2006. J. Immunol. 176:3603-10. (5.6). [cited by applicant]
Barker, Edward et al., Effect of a Chimeric Anti-Ganglioside GD2 Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells, Cancer Res, vol. 51: p. 144-149. [cited by applicant]
Bate-Eya, Laurel et al., (2014), Newly-derived neuroblastoma cell lines propagated inserum-fre media recapitulate the genotype and phenotype of primary neuroblastoma tumours, European Journal of Cancer 50.3: 628-637. [cited by applicant]
Batova, Ayse et al., TheCh14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity inVitro, (1999) ClinCancer Res vol. 5: p. 4259-4263. [cited by applicant]
Beekman, J.M., et al., “Direct interaction between periplakin and FcγRI controls receptor endocytosis and ligand binding capacity” 2004. Proc Natl Acad Sci U S A. 101:10392-10397. (9.8). [cited by applicant]
Beekman, J.M., et al., “FcgRI (CD64) resides constitutively in lipid rafts” 2008 Immuno!. Lett. 116:149-155. [cited by applicant]
Beekman, J.M., et al., “Filamin A stabilizes FcγRI surface expression and prevents its lysosomal routing” 2008. J. Immunol 180:3938-45 (5.6). [cited by applicant]
Beekman, J.M., et al., “Modulation of FcγRI (CD64) ligand binding capacity by periplakin peptides” 2004. J. Biol. Chem. 279:33875-33881. (4.6). [cited by applicant]
Beekman, J.M., et al., “Protein 4.1G binds to a unique motif within the FcγRI cytoplasmic tail” 2008 Mo !. Imm. 45:2069-2075 (3.0). [cited by applicant]
Better, M et al. “Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.” Proc. Natl. Acad. Sci. USA 90: 457-461 (1993). [cited by applicant]
Bevaart, L., et al., “CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells” 2004. Int Immunol. 16:1091-1098. [cited by applicant]
Bevaart, L., et al., “Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity” 2006. Br J Haematol, 132:317-25. (5.0). [cited by applicant]
Bevaart, L., et al., “The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma” 2006. Cancer Res. 66: 1261-1264. (9.3). [cited by applicant]
Beyer, T. et al. “Serum-free production and purification of chimeric IgA antibodies” J. Immunol. Methods 346, 26-37 (2009). [cited by applicant]
Bird, et al., “Single-Chain Antigen-Binding Proteins” (1988) Science 242(4877):423-426. [cited by applicant]
Blaese, R. M., et al. “Hypercatabolismof IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism” J. Clin. Invest. 50, 2331-2338 (1971). [cited by applicant]
Bogdanovich, S., et al. “Human IgG1 antibodies suppress angiogenesis in a target-independent manner” Signal Transduct Target Ther. 2016;1. pii: 15001. Epub Jan. 28, 2016. [cited by applicant]
Bogenmann, E. “A Metastatic Neuroblastoma Model in SCID Mice” Int. J. Cancer vol. 67:379. [cited by applicant]
Bondza, S., et al. ““Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent”” MAbs. Jan. 2020-Dec. 12(1):1792673. doi: 10.1080/19420862.2020.1792673. PMID: 32744151 (4.6). [cited by applicant]
Boross et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 5:1213-1226 (2013). [cited by applicant]
Boross et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96:1822-1830 (2011). [cited by applicant]
Boross, P., et al. “Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice” Immunol Lett. 2014 160:151-157. (2.5). [cited by applicant]
Boross, P., et al. “FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells” J Immunol. Dec. 1, 2014;193(11):5506-14. doi: 10.4049/jimmunol. 13020… [cited by applicant]
Boross, P., et al., “Boosting antibody therapy with complement” Blood. Jun. 21, 2012;119(25):5945-7. (11.8). [cited by applicant]
Boross, P., et al., “Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice” Immunol. Lett. 2011 upon invitation. [cited by applicant]
Boross, P., et al., “Fc receptors” 2008 Encyclopedia of Life Sciences (ELS). Review, chapter, online Wiley's editor. [cited by applicant]
Boross, Peter et al., Mechanisms of action of CD20 antibodies, Am JCancer Res. 2012; 2(6): 676-690. Published online Nov. 20, 2012. [cited by applicant]
Borrok, M.J., et al. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing igG with FcαRI (CD89) binding. MAbs 7, 743-751 (2015). [cited by applicant]
Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156. [cited by applicant]
Braekeveldt, Noemie et al., Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumors, Cancer Lett. 2016 vol. 1;375(2):384-9. doi: 10.1016/j.canlet.2016.02… [cited by applicant]
Brandsma A.M., “Fc receptor inside-out signaling and possible impact on antibody therapy” Immunol Rev. Nov. 2015;268(1):74-87. doi: 10.1111/imr.12332. Review. (12.2). [cited by applicant]
Brandsma AM, et al. “Single nucleotide polymorphisms of the high affinity IgG receptor FcγRI reduce IC binding and downstream effector functions” J Immunol. Aug. 16, 2017. pii: ji1601929. doi: 10.4049/jimmunol.1601929. … [cited by applicant]
Brandsma, A. M. et al. Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front. Immunol. 10, (2019). [cited by applicant]
Brandsma, A. M. et al. Simultaneous targeting of FcgRs and FcaRI enhances tumor cell killing. Cancer Immunol. Res. 3, 1316-1324 (2015). [cited by applicant]
Brandsma, A.M., et al. Clarifying the Confusion between Cytokine and Fc Receptor “Common Gamma Chain” Immunity. Aug. 16, 2016;45(2):225-6. doi: 10.1016/j.immuni.2016.07.006. (IF=24.1). [cited by applicant]
Bronner, I.M., et al., “Association of the leukocyte immunoglobulin G (Fcgamma) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients” Tissue Antigens. 2009 73:586-589 (2.4). [cited by applicant]
Steffen, U. et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat. Commun. 11, (2020). [cited by applicant]
Stemerding, A.M., et al. “ [cited by applicant]
Steurer, W. et al., Ex Vivo Coating of Islet Cell Allografts With Murine CTLA4/Fc Promotes Graft Tolerance, 1995. J Immunol. 155(3):1165-74. [cited by applicant]
Stockmeyer, B. et al. Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. J. Immunol. 165, 5954-5961 (2000). [cited by applicant]
Stork, A.C., et al. “Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy” J Neurol Neurosurg Psychiatry. 2014 85:918-920. (4.9). [cited by applicant]
Story, C. M., et al., A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180, 2377-2381 (1994). [cited by applicant]
Sturtevant, J.N., Biochemical Applications of Differential Scanning Calorimetry 1987, Annual Review of Physical Chemistry 38: 463-488. [cited by applicant]
Suzuki and Cheung, Disialoganglioside GD2 as a therapeutic target for human diseases, 2015, Expert Opinionon Therapeutic Targets vol. 19: p. 349-362. [cited by applicant]
Terme et al., Chimeric Antibody c.8B6 to O-acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 Without Antibody Induced Allodynia, 2014, PLoS One 9(2): e87210. [cited by applicant]
Thotakura, et al., “Enzymatic Deglycosylation of Glycoproteins” Meth. Enzymol. 138: 350-359 (1987). [cited by applicant]
Tian, J., et al., “Accurate Multiplex Gene Synthesis from Programmable DNA Microchips” (2004), Nature 432: 1050-1054. [cited by applicant]
Tolstoshev, P., “Gene Therapy, Concepts Current Trials and Future Predictions” 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596. [cited by applicant]
Tomic, M., et al., A rapid and simple method for introducing specific mutations into any position of DNA leaving all other positions unaltered, Nucleic Acids Research (1990) 18(6):1656. [cited by applicant]
Tramontano, A., et al., “Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the Hb Domains of Immunoglobulins” 71 IS J. Mol. Biol, 215: 175-182 (1990). [cited by applicant]
Treffers, L. W. et al., “IgA-Mediated Killing of Tumor Cells by Neutrophils is Enhanced by CD47-SIRP[alpha] Checkpoint Inhibition”, Cancer Immunology Research, vol. 8, No. 1, Nov. 5, 2019 (Nov. 5, 2019), p. 120-130. [cited by applicant]
Treffers, L. W. et al., FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front. Immunol. 10, 1-13 (2019). [cited by applicant]
Ulfman, L.H., et al. “Effects of bovine immunoglobulins on immune function, allergy and infection” Front Nutr. Jun. 22, 2018;5:52. doi: 10.3389/fnut.2018.00052. eCollection 2018. Review. (4.5). [cited by applicant]
UNITUXIN (dinutuximab) Highlights of Prescribing Information United Therapeutics Corp., Silver Spring, MD 20910, US License No. 1993, p. 19, Copyright 2015. [cited by applicant]
Vajdos, F.F., et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. Jul. 5, 2002;320(2):415-28. [cited by applicant]
Valerius, T, et al., CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med. Jan. 31, 2019;380(5):496-7. doi: 10.1056/NEJMc1816156. (79.3). [cited by applicant]
Valerius, T. et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90, 4485-4492 (1997). [cited by applicant]
Van Bommel, et al., “CD20-Selective Inhibition of CD47-SIRP-alpha ‘Don't Eat Me’ Signaling With A Bispecific Antibody-Derivative Enhances The Anticancer Activity of Daratumumab, Alemtuzumab and Obinutuzumab Oncoimmunolo… [cited by applicant]
Van De Walle, I., et al. “ARGX-117, a therapeutic complement inhibiting antibody targeting C2” J Allergy Clin Immunol. Sep. 11, 2020:S0091-6749(20)31239-2. doi: 10.1016/j.jaci.2020.08.028. (14.9). [cited by applicant]
Van Der Poel, C.E., et al., “Cytokine-induced immune complex binding to the high affinity IgG receptor, FcgRI, in the presence of monomeric IgG” Blood 2010 116:5327-33 (11.8). [cited by applicant]
Van Der Poel, C.E., et al., “Functional characteristics of the high affinity IgG receptor, FcγRI” J. Immunol, 2011. 186:2699-704. (5.6). [cited by applicant]
Van Der Schoot, JMS, et al., “Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.” Science advances vol. 5,8 eaaq1822. Aug. 28, 2019, doi:10.1126/sciadv.aaw1822. [cited by applicant]
Van Egmond, M. et al. FcαRI-positive live Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity. Nat. Med. 6, 680-685 (2000). [cited by applicant]
Van Egmond, M. et al. Human immunoglobulin A receptor (FcαRI, CD89) function in transgenic mice requires both FCR γ chain and CR3 (CD11b/CD18). Blood 93, 4387-4394 (1999). [cited by applicant]
Van Egmond, M. et al., IgA and the IgA Fc receptor. Trends Immunol. 22, 205-211 (2001). [cited by applicant]
Van Royen-Kerkhof, A., et al., “a novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice” 2005. Br J Haematol. 130:130-7. (5.0). [cited by applicant]
Van Royen-Kerkhof, A., et al., “Expression of CD64 (FcgRI) in skin of patients with acute graft-versus-host disease” Bone marrow transplant. Jan. 17, 2011. (2.9). [cited by applicant]
Van Royen-Kerkhof, A., et al., “Flow cytometric determination of FcgRIIa (CD32)” 2004. polymorphism. J. Immunol. Methods. 294:135-144. [cited by applicant]
Van Sorge, N.M., et al., “Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptirs” 2003. Ann Neurol. 53:570-579 (11.9). [cited by applicant]
Van Spriel, A. B., et al. Mac-1 (CD11b/CD18) as Accessory Molecule for FcαR (CD89) Binding of IgA. J. Immunol. 169, 3831-3836 (2002). [cited by applicant]
Van Tetering, G, et al. “Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents” Antibodies (Basel). Dec. 15, 2020;9(4):70. [cited by applicant]
Van Vugt, M.J. , “The FcγRIa (CD64) ligand binding chain triggers MHC class II antigen presentation independently of its associated FcR g-chain” 1999. Blood 94:808-817. [cited by applicant]
Van Vugt, M.J., et al. “The alternatively spliced CD64 transcript FcγRIb2 does not specify a surface expressed isoform” 1999 Eur J Immunol 29:143-149. [cited by applicant]
Verhoeven, A.J., et al., “Inhibition of neutrophil NADPH oxidase assembly by a myristoylated pseudosubstrate of protein kinase C” 1993. J. Biol. Chem. 268:18593-18598 (4.6). [cited by applicant]
Vikström, I.B., et al. “MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL” Cell Death Dis. Aug. 25, 2016;7(8):e2345. doi: 10.1038/cddis.2016… [cited by applicant]
Vyborova A, et al. “γ9δ2T cell diversity and the receptor interface with tumor cells” J Clin Invest. Jun. 2, 2020:132489. doi: 10.1172/JCI132489. Online ahead of print.J Clin Invest. 2020. PMID: 32484803 (12.3). [cited by applicant]
Walbaum, S, et al. “ Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms” J Biol Chem. Jan. 4, 2021:jbc.RA120.015346. doi: 10.1074/jbc.RA120.015346. (4.2). [cited by applicant]
Ward, E. S., et al., Targeting FcRn to Generate Antibody-Based Therapeutics. Trends Pharmacol. Sci. 39, 892-904 (2018). [cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]
Widjaja, I., et al. “Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and is Not Cleaved Displays Prefusion-Like Characteristics” PLoS One. Jun. 2… [cited by applicant]
Wines, B. D., “The Interaction of FcαRI with IgA and Its Implications for Ligand Binding by Immunoreceptors of the Leukocyte Receptor Cluster” J. Immunol. 166, 1781-1789 (2001). [cited by applicant]
Winiarska, M., et al. “Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies” MAbs. 2014 6:1300-1313. [cited by applicant]
Woof, et al., “Structure and function relationships in IgA” Nature (2011, vol. 4, No. 6 p. 590-597. [cited by applicant]
Wu, H., et al., Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. Nov. 19, 1999;294(1): 151-62. [cited by applicant]
Xiao, et al., 1997, Electrophysiological Characteristics of Primary Afferent Fibers After Systemic Administration of Anti-GC2 Ganglioside Antibody, Pain69: 145-151. [cited by applicant]
Yasuma, R., et al. Intravenous immune globulin suppresses angiogenesis in mice and humans. Sig Transduct Target Ther 1, 15002 (2016). https://doi.org/10.1038/sigtrans.2015.2. [cited by applicant]
Evers, M, et al., “The Latest Development with Anti-CD20 Monoclonal Antibodies in Chronic Lymphocytic Leukemia” Expert Opin Biol Ther. Sep. 2018;18(9):973-982. doi: 10.1080/14712598.2018.1508444. Epub Aug. 10, 2018. (4.… [cited by applicant]
Firan, M. et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. Int. Immunol. 13, 993-1002 (2001). [cited by applicant]
Flinsenberg, T.W., et al. “A novel FcyRila Q27W gene variant is associated with common variable immune deficiency through defective FcγRIIa downstream signaling” Clin Immunol. 2014 155:108-117. (4.0). [cited by applicant]
Galluzi, Lorenzo et al, Trial Watch: Monoclonal Antibodies in Cancer Therapy, Jan./Feb. 2012, Oncolmmunology, vol. 1, Issue 1, pp. 28-37. [cited by applicant]
Gazzano-Santoro, H., et al., A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods. Mar. 28, 1997;202(2):163-71. doi: 10.1016/s0022-1759(97)00002-1. PMID: 9107305. [cited by applicant]
Geissmann, F. et al. A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes. J. Immunol. 166, 346-352 (2001). [cited by applicant]
Geller, A. & Yan, J. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy. Front. Immunol. 10, 1-13 (2019). [cited by applicant]
Ghetie, V. et al. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur. J. Immunol. 26, 690-696 (1996). [cited by applicant]
Gillies et al., 1989, High-level expression of chimeric antibodies using adapted cDNA variableregion cassettes, J Immunol Methods, 125, p. 191-202. [cited by applicant]
Gilman et al 2009, Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Repo… [cited by applicant]
Goebl, N. A. et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol. Biol. Cell 19, 5490-5505 (2008). [cited by applicant]
Golay, Josee et al., Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediatesphagocytosis through CD16B more efficiently than rituximab, Immunobiology, Nov. 14, 2013, Blood (2013) 122 (20): 3482-349… [cited by applicant]
Gomes, M. M. et al. Analysis of IgA1 N-glycosylation and its contribution to FcαRI binding. Biochemistry 47, 11285-11299 (2008). [cited by applicant]
Göritzer, et al., “Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes” J. Proteome Res. (2017), 16, 2560-2570. [cited by applicant]
Göritzer, K. et al. Distinct Fcα receptor N-glycans modulate the binding affinity to immunoglobulin A (IgA) antibodies. J. Biol. Chem. 294, 13995-14008 (2019). [cited by applicant]
Graziano, et al., “Antibody-dependent Cell-mediated Cytotoxicity (ADCC)” (2006) Encyclopedia of Life Sciences p. 1-5. [cited by applicant]
Gregory, R. L., et al., Separation of human IgA1 and IgA2 using jacalin-agarose chromatography. J. Immunol. Methods 99, 101-106 (1987). [cited by applicant]
Guss, et al., “Structure of the IgG-binding Regions of Streptococcal Protein G” The EMBO Journal 5(7):1567-1575 (1986). [cited by applicant]
Hakimuddin, T., et al. A Chemical Method for the Deglycosylation of Proteins Arch. Biochem. Biophys. 259: 52 (1987). [cited by applicant]
Heystek, H. C., et al., Human Immature Dendritic Cells Efficiently Bind and Take up Secretory IgA Without the Induction of Maturation. J. Immunol. 168, 102-107 (2002). [cited by applicant]
Hidalgo, A., et al., The Neutrophil Life Cycle. Trends Immunol. 40, 584-597 (2019). [cited by applicant]
Hiemstra, Peter S. et al., Activation of the alternative pathway of complement by humanserum IgA European journal of immunology.1987;17(3):321-6. [cited by applicant]
Hochleitner, E.O., et al., “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometri… [cited by applicant]
Holliger, P., et al., Engineered Antibody Fragments and the Rise of Single Domains Nat. Biotech., 23(9):1126-1129 (2005). [cited by applicant]
Holt, A.J., et al. “Domain Antibodies: Proteins for Therapy” Trends Biotechnol (2003): 21: 484-490. [cited by applicant]
Huls, G. et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 59, 5778-5784 (1999). [cited by applicant]
Huston, J.S., et al., Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fc Analogue Produced in [cited by applicant]
Idosogie et al., Mapping of the C1q Binding Site on Rituxan, aChimeric Antibody with a Human IgG1 Fc, 2000. Ulmmunol. 164(8):4178-84. [cited by applicant]
Idusogie, et al. Engineered antibodies with increased activity to recruit complement. J Immunol. Feb. 15, 2001;166(4):2571-5. [cited by applicant]
International Search Report and Written Opinion for corresponding PCT Application No. PCT/2020014617 issued Aug. 17, 2020. [cited by applicant]
International Search Report and Written Opinion for corresponding PCT Application No. PCT/NL2019/050712 issued Mar. 30, 2020. [cited by applicant]
International Search Report and Written Opinion for corresponding PCT Application No. PCT/US2019/058648 issued Apr. 9, 2020. [cited by applicant]
Israel, E. J., et al. Increased clearance of IgG in mice that lack β2-microglobulin: Possible protective role of FcRn. Immunology 89, 573-578 (1996). [cited by applicant]
Jacobino, Sr, et al. “Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo” MAbs. Apr. 2018;10(3):453-462. doi: 10.1080/19420862.2018.1433974. … [cited by applicant]
Jansen, B., et al., “Os9 interacts with DC-stamp and modulates its intracellular localization in response to TLR igation” 2009. Mol. Imm 46:505-515 (3.0). [cited by applicant]
Jarvis, G.A., et al., Human IgA1 initiates Compliment Mediated Killing of Neisseria Meningitis, J Immunol. 1989;143(5):1703-9. [cited by applicant]
Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. Jul. 2009;30(7):356-62. doi:10.1016/j.tips.2009.04.007. Epub Jun. 22, 2009. Review. PubMed PMID:… [cited by applicant]
Johansen, F. E. et al., Regulation of the polymeric immunoglobulin receptor and IgA transport: New advances in environmental factors that stimulate plgR expression and its role in mucosal immunity. Mucosal Immunol. 4, 5… [cited by applicant]
Johansen, F., et al., “Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin” European Journal of Immunology (1999) vol. 29, No. 5. [cited by applicant]
Junghans, R. P., et al., The protection receptor for IgG catabolismis the β2-microglobulin-containing neonatal Intestinal transport receptor. Proc. Natl. Acad. Sci. U. S. A. 93, 5512-5516 (1996). [cited by applicant]
Keler, T. et al. Differential Effect of Cytokine Treatment on Fcα Receptor I-and Fcγ Receptor I-Mediated Tumor Cytotoxicity by Monocyte-Derived Macrophages. J. Immunol. 164, 5746-5752 (2000). [cited by applicant]
Kelton, C. et al. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Arch. Biochem. Biophys. 526, 219-225 (2012). [cited by applicant]
Kelton, W. et al. IgGA: A 'cross-isotype' engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem. Biol. 21, 1603-1609 (2014). [cited by applicant]
Kierkels GJJ, et al. “Identification of a tumor-specific allo-HLA-restricted γδTCR” Blood Adv. Oct. 8, 2019;3(19):2870-2882. doi: 10.1182/bloodadvances.2019032409. [cited by applicant]
Kim, Jin-Kyoo et al., Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis Eur. J. Immunol. (1994) 24:542-548. [cited by applicant]
Kruijsen, D., et al., “Serum antibodies critically affect virus specific CD4+/CD8+ T cell balance during RSV Infections” J. Immunol, 2010, 185:6489-98 (5.6). [cited by applicant]
Kunkel, T.A., et al., Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection, Methods Enzymol,, 154:367-82, 1987. [cited by applicant]
Kuribayashi, F., et al., “A novel polymorphism in the coding region of CYBB, the human gp91-phox gene” 1996. Human Genetics 97:611-613. [cited by applicant]
Ladenstein et al.2013, Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients A SIOPEN phase 1 study, MAbs 5(5): 801-809. [cited by applicant]
Lamminmaki, U., et al., Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol, JBC 2001, 276:36687-36694. [cited by applicant]
Brandsma, Arianne M., et al. “Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.” Science signaling vol. 11,540 eaaq0891. Jul. 24, 2018, doi:10.1126/scisignal.aaq0891. [cited by applicant]
Brandtzaeg, P. & Prydz, H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 311, 71-73 (1984). [cited by applicant]
Bras AE, et al. “CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping” Cytometry B Clin Cytom. Mar. 2019;96(2): 134-142. doi: 10.1002/cyto.b. 21745 (2.8). [cited by applicant]
Brezski, Randall et al., Immunoglobulin isotype Knowledge and Application to FC Engineering, Current Opinions in Immunology, 2016, 40:62-69. [cited by applicant]
Brodzik, R., et al., “Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells” Proc Nat! Acad Sci U S A. 2006. 103:8804-8809 (9.8). [cited by applicant]
Broeke Ten T., “Meeting report on immunoreceptors 2014” FASEB J. Mar. 2015;29(3):740-4 (5.5). [cited by applicant]
Broeke Ten, T, et al. “FcαRI Dynamics Are Regulated by GSK-3 and PKCZ During Cytokine Mediated Inside-Out Signaling” Front Immunol. Jan. 31, 2019;9:3191. doi: 10.3389/fimmu.2018.03191. (6.4). [cited by applicant]
Bruchelt et al (1989); Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors, Immunol Lett 22(3): 217-220. [cited by applicant]
Bruhns et al. Specificity and Affinity of Human Fc Receptors and Their Polymorphic Variants for Human IgG Subclasses. Blood 113(16):3716-3725 (2009). [cited by applicant]
Brunke, C. et al. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 min(1) antibody. MAbs 5, 936-945 (2013). [cited by applicant]
Büll, C. et al. “Targeted Delivery of a Sialic Acid-Blocking Glycomimetic to Cancer Cells Inhibits Metastatic Spread” ACS Nano. Jan. 27, 2015;9(1):733-45. Epub Jan. 14, 2015 (12.0). [cited by applicant]
Carayannopoulos, L., et al. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Cα2 and Cα3 in human IgA1. J. Exp. Med. 183, 1579-1586 (1996). [cited by applicant]
Carter, P., et al., “High Level [cited by applicant]
Casset, F., et al., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochem Biophys Res Commun. Jul. 18, 2003;307(1):198-205. [cited by applicant]
Challacombe, S. J., et al., Estimation of the intravascular half-lives of normal rhesus monkey IgG, IgA and IgM. Immunology 36, 331-338 (1979). [cited by applicant]
Chao et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699-713 (2010). [cited by applicant]
Chao Mark P et al, “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”, 20100903, vol. 142, No. 5, Sep. 3, 2010 (Sep. 3, 2010), p. 699-713. [cited by applicant]
Chaplan et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63 (1994). [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen” J. Mol. Biol. 293:865-881 (1999). [cited by applicant]
Chen, Y., et al., Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. Nov. 5, 1999;293(4):865-81. [cited by applicant]
Cheung, Irene et al., Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor,20… [cited by applicant]
Cheung, Nai-Kong V. at al (2014), Key Role for Myeloid Cells: Phase II Results of Anti-GD2 Antibody3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor for Chemoresistant Osteomedullary Neuroblastoma, Int J Cancer … [cited by applicant]
Cheung, Nai-Kong V. et al., 2012, Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo, Oncoimmunology 1.4: 477-486. [cited by applicant]
Chintalacharuvu, K. R., et al., Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J. Immunol. 152, 5299-304 (1994). [cited by applicant]
Chintalacharuvu, K.R., et al., Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin. Immunol. 101, 21-31 (2001). [cited by applicant]
Choa, et al., “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma”, J. Cell (2010) vol. 142, No. 5 pp. 699-713. [cited by applicant]
Chothia, C., et al., Structural repertoire of the human VH segments. J Mol Biol. Oct. 5, 1992;227(3):799-817. doi: 10.1016/0022-2836(92)90224-8. PMID: 1404389. [cited by applicant]
Chothia, et al., Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. Aug. 20, 1987;196(4):901-17. doi: 10.1016/0022-2836(87)90412-8. PMID: 3681981. [cited by applicant]
Clarkson, T., et al., “Making Antibody Fragments Using Phage Display Libraries” Nature 352:624-628 (1991). [cited by applicant]
Daha, M.R., et al., “Isolation from purulent sputum of an antigen with Wegener's granulomatosis” 1990. Neth. J. Med., 36:117-120. [cited by applicant]
Davies J, et al. ‘Camelising’ human antibody fragments: NMR studies on VH domains. FEBS Lett. Feb. 21, 1994;339(3):285-90. doi: 10.1016/0014-5793(94)80432-x. PMID: 8112468. [cited by applicant]
Davis, J. H. et al., SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein E… [cited by applicant]
De Haij, S., et al.., “In vivo cytotoxicity of type I CD20 antibodies critically depends on FcR ITAM signaling” 2010. Cancer Research 2010 70:3209-17 (9.3). [cited by applicant]
De Pascalis, R., et al., Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibod… [cited by applicant]
Dechant, M. et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100, 4574-4580 (2002). [cited by applicant]
Dechant, M. et al. Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor. J. Immunol. 179, 2936-2943 (2007). [cited by applicant]
Delacroix, D. L., Elkon, et al. Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J. Clin. Invest. 71, 358-367 (1983). [cited by applicant]
Den Hartog, G, et al. “Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk” PLoS One. Nov. 6, 2014;9(11):e112047 (3.5). [cited by applicant]
Deo, Y. M., et al., Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J. Immunol. 160, 1677-8… [cited by applicant]
Derbyshire, et al., A simple and efficient procedure for saturation mutagenesis using mixed oligodeoxynucleotides. Gene. 1986;46(2-3):145-52. doi: 10.1016/0378-1119(86)90398-7. PMID: 3803923. [cited by applicant]
Dickinson, B. L. et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest. 104, 903-911 (1999). [cited by applicant]
Dooley, H. et al. Antibody repertoire development in cartilaginous fish. Dev Comp Immunol. 2006;30(1-2):43-56. doi: 10.1016/j.dci.2005.06.022. PMID: 16146649. [cited by applicant]
Edge, A.S., et al. Deglycosylation of glycoproteins by trifluoromethanesulfonic acid. Anal Biochem. Nov. 15, 1981;118(1):131-7. doi: 10.1016/0003-2697(81)90168-8. PMID: 6175244. [cited by applicant]
Ehring, Hanno, Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions, Analytical Biochemistry, vol. 267, Issue 2, 1999, pp. 252-259, ISSN… [cited by applicant]
Eijkelkamp et al., GRK2: A Novel Cell-Specific Regulator of Severity andDuration of Inflammatory Pain, J. Neuroscience, Feb. 20, 2010, pp. 2138-2149. [cited by applicant]
Eijkelkamp, et al., “IL4-10 Fusion Protein is a Novel Drug to Treat Persistent Inflammatory Pain” The Journal of Neuroscience, Jul. 13, 2016; 36(28):7353-7363. [cited by applicant]
Endo, Y, et al., High-throughput, genome-scale protein production method based on the wheat germ cell-free expression system. Biotechnol Adv. Nov. 2003;21(8):695-713. doi: 10.1016/s0734-9750(03)00105-8. PMID: 14563476. [cited by applicant]
Engen, J.R., & Smith, D.L., Peer Reviewed: Investigating Protein Structure and Dynamics by Hydrogen Exchange MS Anal. Chem. (2001) 73:256A-265A. [cited by applicant]
Evers M, et al, “Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies” MAbs. Jan. 2020-Dec.;12(1):1795505. doi: 10.1080/19420862.2020.1795505. PMID: 32744145 (4.6). [cited by applicant]
Evers M, et al. “Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells”. J Immunol. Apr. 15, 2018;200(8):2515-2516. (5.6). [cited by applicant]